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centrations were measured in patients after a first throm-
botic event.9 Because these markers were measured at least
6 months after the thrombotic event, it was unlikely that
the thrombosis itself was responsible for the increased
plasma levels. Therefore, it was suggested that inflamma-
tion was a risk factor for DVT. In the latter study, the con-
centration of another inflammatory parameter, C-reactive
protein (CRP), was also increased in patients with throm-
bosis.10 However, in a prospective study, higher baseline
CRP concentration was associated with a higher risk of
future myocardial infarction and stroke but not with
DVT.11 In contrast to the suggestion that low-grade
inflammation is a risk factor, it can also be hypothesized
that acute DVT causes an inflammatory response, which
may persist for a longer period.
To test this hypothesis, we studied the question of
whether an immediate systemic inflammatory response
occurs in DVT. To answer this question, we determined
interleukin-6, interleukin-8, and CRP concentrations as
inflammatory markers in patients with DVT, both at diag-
nosis and during the follow-up period, and compared
these with control subjects on the day of presentation.
Furthermore, we analyzed the diagnostic value of the
inflammatory markers on the day of admission.
METHODS
Patients. The study population consisted of patients
who participated in a previous study that dealt with the
exclusion of DVT with D dimer testing.12 In short, 112
consecutive outpatients were referred to the emergency
Deep vein thrombosis (DVT) occurs with an inci-
dence rate of 1 to 2 per 1000. Known risk factors are defi-
ciencies of protein C, protein S, antithrombin III, factor V
Leiden and a mutation of prothrombin (factor II), immo-
bilization, surgery, trauma, pregnancy, malignant disease,
use of oral contraceptives, hyperhomocysteinemia, and
elevated concentrations of factor VIII.1-3 In the last few
years, several new risk factors have been detected, such as
factor IX,4 factor XI,5 and thrombin activatable fibrinoly-
sis inhibitor.6
Chronic systemic inflammation is a risk factor for ath-
erosclerosis, and it has been shown that markers of low-
grade systemic inflammation are associated with a future
risk of coronary heart disease.7 The relationship between
inflammation and venous thrombosis remains less well
studied. An increase of the concentration of inflammatory
markers interleukin-6, interleukin-8, and monocyte
chemoattractive protein–1 was found in patients with
recurrent DVT,8 and elevated interleukin-8 plasma con-
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Objective: Deep vein thrombosis (DVT) is a multifactorial disease. Recently, inflammation has been suggested as a risk
factor for DVT. The question is whether inflammation is a cause of venous thrombosis or rather a result of the throm-
botic process.
Methods: We studied the inflammatory response in the acute phase of DVT with interleukin-6, interleukin-8, and C-reac-
tive protein (CRP) as inflammatory markers. Plasma concentrations were measured on the day of admission (day 0) in 40
patients with acute DVT confirmed with phlebography and in 33 patients with clinical suspicion of DVT but negative phle-
bography results (controls). In patients with DVT, inflammatory markers were also examined on five subsequent days.
Results: On day 0, the median concentrations in plasma of interleukin-6, interleukin-8, and CRP were 15.0 pg/mL
(range, <3 to 70 pg/mL), 7.0 pg/mL (range, <3 to 76 pg/mL), 37.5 mg/L (range, <7 to 164 mg/L), respectively, in
the patient group and less than 3 pg/mL (range, <3 to 11 pg/mL; P < .001), 6.0 pg/mL (range, <3 to 52 pg/mL; 
P = .08), and 5.0 pg/L (range, <7 to 66 pg/L; P < .001), respectively, in the controls. During the next days, inter-
leukin-6 concentration showed a gradual decline in patients with DVT from 15.0 to 5.5 pg/mL (P < .001), interleukin-
8 concentration was relatively constant in time, and CRP concentration declined from 37.5 to 21.5 mg/L (P = .01).
Conclusion: Our data show an apparent inflammatory response with highest measured concentrations of inflammatory
markers on the day of admission and a subsequent decrease during the next days. This response supports the hypoth-
esis that elevated inflammatory markers are a result rather than a cause of venous thrombosis. (J Vasc Surg
2002;35:701-6.)
department because of clinical suspicion of DVT. The
patients were excluded with one or more of the following
criteria: treatment with anticoagulant therapy (n = 1),
recent surgery less than 8 days previously (n = 0), refusal
or inability to give informed consent (n = 5), and inabil-
ity for ascending contrast venography or inadequate
results of the venographic examination (n = 7). Ninety-
nine patients were included and evaluated with ascending
contrast venography for the diagnosis of DVT, defined as
a persistent intraluminal filling defect in at least two pro-
jections. When DVT was diagnosed, the patients were
admitted to the hospital and treated with intravenous
heparin therapy for a minimum of 5 days. Warfarin ther-
apy was started concurrently for 3 months. When DVT
was excluded, the patients were discharged and no further
follow-up examination was performed (these patients are
further named control subjects). The study was restricted
to patients with a complete set of sera for the day of
admission and the 5 subsequent days because, in some
patients, after measurement of D dimers, no sera
remained. The study protocol was approved by the
Institutional Review Board of the Sint Joseph Hospital
Veldhoven, and informed consent was obtained from all
the study participants.
Blood collection. Blood was collected within 2 hours
of presentation in the emergency department and before
administration of heparin therapy if DVT was diagnosed.
After a positive diagnosis of DVT and admission to the
hospital, blood was drawn daily between 8:00 and 10:00
AM for the next 5 days. Blood was collected into 4.5-mL
siliconized glass vacutainer tubes that contained 0.45 mL
of 0.109 mol/L sodium citrate. Platelet poor plasma was
prepared with centrifugation at 3000g for 15 minutes at
20°C, mixed, aliquoted, frozen, and stored at –80°C until
analysis. At the time of the assay, the samples were thawed
in a waterbath at 37°C for 10 minutes and, after mixing,
were allowed to stand at room temperature for at least 15
minutes before use.
Analysis of plasma concentrations of interleukin-6,
interleukin-8, C-reactive protein, and D dimer.
Interleukin-6 and interleukin-8 concentrations were
determined with a commercially available enzyme-linked
immunosorbent assay (Central Laboratory of the
Netherlands Red Cross Blood Transfusion Service,
Amsterdam, the Netherlands). These enzyme-linked
immunosorbent assay kits are calibrated according to the
standards of the National Institute for Biological
Standards and Control (Potters Bar, United Kingdom).
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Fig 1. Plasma levels in control subjects and patients with deep vein thrombosis (DVT) of (A) interleukin-6 (IL-6), (B) interleukin-




The detection limit is 3.0 pg/mL for both interleukin-6
and interleukin-8. CRP was assayed with an immunoassay
on a Vitros 250 (Ortho Clinical Diagnostics, Rochester,
NY), with a detection limit of 7 g/mL.
In the previous study, 13 D dimer methods were
tested.12 The Tinaquant D dimer assay (Roche
Diagnostics, Mannheim, Germany) was one of the two
assays with the highest sensitivity, so the results of the
Tinaquant assay were used for this study. 
Statistics. The significance of differences in concentra-
tions between the patients and the control subjects was
tested with the Mann-Whitney test. P values of less than .05
were considered significant. Furthermore, we compared the
presence of elevated plasma concentrations in control sub-
jects and patients with DVT with the 2 test. Elevated lev-
els of interleukin-6, interleukin-8, and CRP were defined as
concentrations of more than the 90th percentile of the dis-
tribution in the control subjects. The significance of the dif-
ference in concentration during the time course was
evaluated with the Mann-Whitney test for paired samples.
The correlation coefficient was used for the assessment
of the relation between inflammatory parameters and D
dimer levels. The correlation was defined as good if more
than 0.75, as moderate if between 0.50 and 0.75, and as
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poor if less than 0.50. With the Pearson correlation test,
the significance of the correlation coefficient was calculated
and defined as significant at the .01 level (two-tailed). The
diagnostic values of the inflammatory parameters were
evaluated with receiver operating curves, which were con-
structed for interleukin-6, interleukin-8, CRP, and D
dimer by plotting sensitivity (true positive fraction)
towards one specificity (false-positive fraction). Areas
under the curves (AUCs) were derived from these curves
as an estimate of the overall diagnostic performance.
RESULTS
In 50 of the 99 included patients, the clinical suspicion
of DVT was confirmed with venography. In the remaining
49 patients, the diagnosis was excluded. Plasma was avail-
able in 40 of the patients with DVT (17 male and 23
female) and in 33 control subjects (12 male and 21
female). In the other patients, after measurement of D
dimers, not enough sera remained for all the days. There
are no differences in the clinical characteristics of the
patients included in this study when compared with all the
patients. The median age of the patients with DVT was
55.7 years (range, 27 to 87 years) and of the control sub-
jects was 52.0 years (range, 23 to 79 years). The median
Fig 2. Median levels of inflammatory parameters in patients with deep vein thrombosis on day of admission (day 0) and during 5 sub-
sequent days. A, Interleukin-6 (IL-6). B, Interleukin-8 (IL-8). C, C-reactive protein (CRP). Dotted lines represent 90th percentile of
distribution of control subjects on day of presentation.
A
B C
duration of symptoms was 8 days (range, 1 to 42 days).
Five patients (7%) had symptoms for longer than 10 days.
The following risk factors for DVT were present in 18
patients: malignant disease (n = 5), immobilization (n =
5), recent trauma (n = 3), oral contraceptive use (n = 2),
and previous operation (n = 3; <8 days were excluded). Of
the DVT group, four patients had distal thrombosis and
36 had proximal thrombosis.
At the day of admission, the median plasma concen-
trations of interleukin-6, interleukin-8, and CRP were
higher in the patients with DVT as compared with the
control subjects (Fig 1). In the patients with DVT, the
median plasma levels of interleukin-6, interleukin-8, and
CRP were 15.0 pg/mL (range, <3 to 70 pg/mL), 7.0
pg/mL (range, <3 to 76 pg/mL), and 37.5 mg/L (range,
<7 to 164 mg/L), respectively, and in the control subjects
were less than 3 pg/mL (range, <3 to 11 pg/mL; P <
.001), 6.0 pg/mL (range, <3 to 52 pg/mL; P = .08), and
5.0 pg/L (range, <7 to 66 pg/L; P < .001), respectively.
The 90th percentile of control subjects was, respectively,
7.6 pg/mL, 9.8 pg/mL, and 36.2 mg/L. In patients with
DVT, elevated plasma levels of interleukin-6 were found in
64%, of interleukin-8 in 39%, and of CRP in 51%, as com-
pared with 10% in the control group (P < .01). Although
the number of patients with distal thrombosis is small (n =
4), these patients had considerably lower levels of inflam-
matory markers (median plasma levels: interleukin-6, <3
pg/mL; interleukin-8, 5.5 pg/mL; and CRP, 6.0 mg/L)
than did patients with proximal DVT (median plasma lev-
els: interleukin-6, 19.4 pg/mL; interleukin-8, 11.3
mg/mL; and CRP, 53.2 mg/L). There were no differ-
ences in inflammatory markers between patients with
known risk factors, such as malignant disease or recent
trauma, and patients with idiopathic thrombosis.
During the follow-up period, levels of interleukin-6
declined to 5.5 pg/mL after 5 days of treatment (Fig 2).
Median levels of interleukin-8 did not change over time.
The median CRP level showed an initial rise on the 2nd
and 3rd day from 37.5 mg/L to 50.0 and 51.0 mg/L and
then declined to 21.5 mg/L. Despite the decline in inter-
leukin-6 and CRP levels, the concentrations after 5 days
were still increased as compared with the controls at the
day of presentation (interleukin-6, 5.5 pg/mL versus <3.0
pg/mL; P = .003; and CRP, 21.5 mg/L versus 5.0 mg/L;
P = .001). At day 5, elevated levels (>90th percentile of
controls) of interleukin-6, interleukin-8, and CRP were
still found in 35%, 41%, and 39%, respectively, of patients
with DVT (all P < .01).
At day of presentation, the median D dimer levels
were 4.50 mg/L in patients with DVT versus 0.54 mg/L
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Fig 3. Receiver operating curve analysis of accuracy of (A) interleukin-6 (IL-6), (B) interleukin-8 (IL-8), (C) C-reactive protein (CRP),





in controls. The correlation with interleukin-6, inter-
leukin-8, and CRP was only moderate (interleukin-6: r =
0.62; n = 70; P < .01; interleukin-8: r = 0.46; n = 65; P <
.01; CRP: r = 0.72; n = 62; P < .01)). The receiver oper-
ating curves for interleukin-6, interleukin-8, CRP, and D
dimer levels are shown in Fig 3. AUCs of the inflamma-
tory parameters were 0.91, 0.63, and 0.88, respectively, as
compared with the AUCs of D dimers (0.96).
DISCUSSION
This study shows an apparent systemic inflammatory
response with elevated plasma levels of interleukin-6,
interleukin-8, and CRP in patients with DVT. Interleukin-
6 and CRP levels showed a gradual decline during treat-
ment, whereas interleukin-8 levels remained elevated in
time. These results support the hypothesis that inflamma-
tion is a result of the thrombotic process rather than a
cause of DVT.
It has been suggested that low-grade inflammation is
a cause of DVT because elevated interleukin-6, inter-
leukin-8, and monocyte chemoattractive protein–1 con-
centrations were found in patients after a thrombotic
event.8,9 We cannot exclude that higher levels of inflam-
matory markers can be present because of risk factors in
some of the patients with DVT (like malignant disease or
recent trauma). However, there was no difference in
markers between patients with idiopathic thrombosis or
patients with a risk factor. It could be expected that, in
case of persistent systemic inflammation as a cause of
DVT, concentrations of inflammatory markers are steady
instead of declining. Although this alternative hypothesis
of low-grade persistent inflammation as a cause of DVT is
not finally excluded, the course of the inflammatory mark-
ers is in our opinion strongly suggestive for the hypothe-
sis that DVT is followed by an inflammatory response.
Except for elevated CRP levels at the diagnosis of
DVT,13,14 no other studies have been published on
inflammatory markers in the acute phase of DVT in
humans. In an experimental baboon model of DVT,
interleukin-6 and interleukin-8 concentrations peaked on
day 2 after stasis-induced DVT. Unlike other cytokines,
only interleukin-6 showed a significant relation with the
extent of thrombosis on fibrinogen scanning. DVT was
associated with a venous wall inflammatory response that
consisted of an early neutrophil infiltration into the vein
wall, followed by extravasation of monocytes, macro-
phages, and lymphocytes.15 The inflammatory response
in the vein wall could be visualized with gadolinium-
enhanced magnetic resonance venography that showed
enhancement around the thrombosed veins, which
diminished in approximately 2 weeks.16 In our study, dur-
ing treatment in the subsequent days after the diagnosis
of DVT, interleukin-6 and CRP levels declined and inter-
leukin-8 levels were relatively constant. CRP concentra-
tion peaked during 2 days, similar to another study in
DVT.13 Because the inflammatory response is initiated
and propagated by further thrombosis,15 the decline of
markers is most probably the effect of treatment with
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anticoagulants. Although antiinflammatory agents may
prevent DVT17 and heparin possesses antiinflammatory
properties distinct from its anticoagulant properties and
inhibited vein wall neutrophils in an animal thrombosis
model, the mechanism is unknown and the antiinflamma-
tory effects may not be cytokine-mediated.18 For this rea-
son, we think that the course of the inflammatory markers
is not caused by the antiinflammatory effects of the treat-
ment with heparin but is the result of decrease of the
thrombotic process.
The control subjects in this study were patients with a
clinical suspicion of DVT with negative phlebography
results. Because the main priority was exclusion of DVT,
an alternative diagnosis was not always clear and the con-
trol subjects were referred to their general practitioner.
The differential diagnosis of DVT includes, for example,
lymphedema, muscle trauma, hemorrhage, arthritis, ten-
dinitis, and erysipelas. Some of these disorders may also
cause elevations of inflammatory parameters. Although in
most patients no substantial elevation of inflammatory
parameters was found, it can be expected that in compar-
ison with healthy controls the inflammatory response in
DVT is even more apparent.
Several earlier studies showed elevated CRP levels at
the diagnosis of DVT. Although CRP concentration was
not a reliable marker for exclusion of DVT, the sensitivity
of an elevated CRP level at time of diagnosis was 72% to
100%.13,14 As in our study, lower CRP levels were found
in patients with distal thrombosis.13 When elevation of
inflammatory markers are supposed to be the result of the
DVT, they might also be used as diagnostic markers for
DVT. Therefore, we looked at the diagnostic value of
these markers as compared with D dimer. Although in our
study, D dimer levels showed the highest sensitivity and
specificity, the AUCs of interleukin-6 and CRP compared
with D dimer can also be considered as good. The corre-
lation of interleukin-6, interleukin-8, and CRP levels with
D dimer levels at diagnosis was only moderate. Although
it has been suggested that initial D dimer levels may be
related to the extent of the thrombosis, this correlation is
relatively weak. This may be because of differences in fi-
brinolytic activity between individuals.19 It appears that
the processes of fibrinolysis and inflammation may interact
in DVT, but the extent of the inflammatory process can
not be estimated with determination of D dimer levels.
In conclusion, in the acute phase of DVT, we found an
apparent systemic inflammatory response with highest
measured concentrations of inflammatory markers on day
of admission and a subsequent decrease during the next
days. This supports the hypothesis that elevated cytokines
in patients with DVT are more likely to be a result of the
thrombotic process rather than a cause of DVT. 
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